Program
Atorvastatin
Also written as “atorvastatin”, “Atorvastatin 20 mg” and “Comparator: atorvastatin”.
Its studies are mostly in Hypercholesterolemia · Dyslipidemias · Hyperlipidemias · Diabetes Mellitus, Type 2 · Cardiovascular Diseases, led by 22 companies.
Drug pageAtorvastatin: every studyMany companies study it; this page follows only the 105 they lead. All 640 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 290 open or running | phase 4since Aug 30, 2005 | Aug 25, 2005 | none ahead |
| Organonits history only | 200 open or running | phase 4since Apr 1, 2008 | Sep 23, 2004 | none ahead |
| Pfizerits history only | 160 open or running | phase 4since Sep 6, 2005 | Aug 22, 2005 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 60 open or running | phase 4since Nov 16, 2009 | Nov 16, 2009 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 60 open or running | phase 1since Jul 18, 2012 | Jul 18, 2012 | none ahead |
| GlaxoSmithKlineits history only | 60 open or running | phase 3since Dec 15, 2011 | Dec 11, 2006 | none ahead |
| Astellas Pharmaits history only | 30 open or running | phase 4since Dec 5, 2006 | Dec 5, 2006 | none ahead |
| Daiichi Sankyoits history only | 30 open or running | phase 4since Sep 16, 2008 | Sep 16, 2008 | none ahead |
| Midas Pharmaits history only | 20 open or running | phase 1since Jan 23, 2020 | Jan 23, 2020 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since Dec 20, 2011 | Dec 20, 2011 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 1since Sep 21, 2012 | Sep 21, 2012 | none ahead |
| Clinical Research Managementits history only | 10 open or running | phase 2since Mar 1, 2015 | Mar 1, 2015 | none ahead |
| Cumberland Pharmaceuticalsits history only | 10 open or running | phase 2since Jul 19, 2018 | Jul 19, 2018 | none ahead |
| Daewon Pharmaceuticalits history only | 10 open or running | phase 3since Jul 24, 2023 | Jul 24, 2023 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Oct 26, 2016 | Oct 26, 2016 | none ahead |
| Dr. Md. Alimur Rezaits history only | 10 open or running | phase 4since Jan 17, 2025 | Jan 17, 2025 | none ahead |
| Huons Globalits history only | 11 open or running | phase 1since Aug 5, 2026 | Aug 5, 2026 | Apr 2027phase 1 · NCT07784608 |
| Intarcia Therapeuticsits history only | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Jeil Pharmaceuticalits history only | 10 open or running | phase 1since Mar 5, 2018 | Mar 5, 2018 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 10 open or running | phase 3since Apr 29, 2021 | Apr 29, 2021 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 9, 2009 | Sep 9, 2009 | none ahead |
| Samil Pharmaceuticalits history only | 10 open or running | phase 1since Oct 13, 2015 | Oct 13, 2015 | none ahead |
Also a collaborator on its studies: Parexel, Pharma Medica Research, Merck, Regeneron Pharmaceuticals, MDS Pharma Services, Celerion, Sanofi and Basilea Pharmaceutica International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Aug 25, 2005.
- Sep 6, 20055 phase 4 studiesNCT00150384, NCT00159718, NCT00174330 and 2 more
- Feb 28, 2006Phase 3 study in HypertensionNCT00330785 · 1,250 enrolled · Canada, United Kingdom
- Jun 20, 2006Phase 3 study in Cardiovascular DiseasesNCT00343655 · 160 enrolled · United States
- Feb 28, 20072 phase 4 studies in Coronary Artery DiseaseNCT00442845, NCT00442325
- Apr 4, 2007Phase 4 study in Arrhythmias, CardiacNCT00457340 · 220 enrolled · Belgium, Greece
- Oct 4, 2007Phase 4 study in DyslipidemiasNCT00540293 · 425 enrolled · Korea, Republic of
- Mar 14, 20086 phase 4 studiesNCT00640549, NCT00645424, NCT00644670 and 3 more
- Jul 31, 2008Phase 4 study in Acute Coronary SyndromeNCT00728988 · 499 enrolled · China, Korea, Republic of
- Aug 21, 2008Phase 1 study in Pediatric Heterozygous HypercholesterolemiaNCT00739999 · 39 enrolled · Canada, Greece, Norway
- Sep 22, 2008Phase 1 study in HypercholesterolemiaNCT00758004 · 76 enrolled · United States
- Jan 21, 2009Phase 3 study in Hyperlipoproteinemia Type IINCT00827606 · 272 enrolled · United States, Belgium, Canada and more
- Feb 13, 2009Phase 4 study in HypercholesterolemiaNCT00844376 · 12 enrolled · United States
- Jun 8, 2009Phase 4 study in HypercholesterolemiaNCT00917579 · 76 enrolled · United States
- Oct 14, 2013Phase 3 study in HypercholesterolemiaNCT01964326 · 1,311 enrolled · United States
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rosuvastatinrule | AstraZeneca | phase 4 | 184 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
All 29 Viatris leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01964326Hypercholesterolemia · United States | 3 | Completed | Dec 2014 | 1,311 |
| NCT00917579Hypercholesterolemia · United States | 4 | Completed | Sep 2008 | 76 |
| NCT00844376Hypercholesterolemia · United States | 4 | Completed | Mar 2008 | 12 |
| NCT00827606Hyperlipoproteinemia Type II · United States, Belgium, Canada and more | 3 | Completed | Oct 2013 | 272 |
| NCT00758004Hypercholesterolemia · United States | 1 | Completed | Mar 2009 | 76 |
| NCT00739999Pediatric Heterozygous Hypercholesterolemia · Canada, Greece, Norway | 1 | Completed | May 2009 | 39 |
| NCT00728988Acute Coronary Syndrome · China, Korea, Republic of | 4 | Completed | Apr 2010 | 499 |
| NCT00647543Dyslipidemias · Thailand | 4 | Completed | 242 | |
| NCT00645151Dyslipidemias · Brazil, Chile, Colombia and more | 4 | Completed | 512 | |
| NCT00644709Dyslipidemias · Belgium | 4 | Completed | 196 | |
| NCT00645424Hyperlipidemias · Taiwan | 4 | Completed | 155 | |
| NCT00644670Dyslipidemias · Belgium | 4 | Completed | 232 | |
| NCT00640549Hyperlipidemias · Germany | 4 | Terminated | 41 | |
| NCT00540293Dyslipidemias · Korea, Republic of | 4 | Completed | May 2008 | 425 |
| NCT00457340Arrhythmias, Cardiac · Belgium, Greece | 4 | Completed | 220 | |
| NCT00442845Coronary Artery Disease · Cameroon, Canada, Italy and more | 4 | Completed | Feb 2004 | 2,080 |
| NCT00442325Coronary Artery Disease · Greece, Hungary, Ireland and more | 4 | Completed | 595 | |
| NCT00343655Cardiovascular Diseases · United States | 3 | Terminated | 160 | |
| NCT00330785Hypertension · Canada, United Kingdom | 3 | Completed | 1,250 | |
| NCT00174330Hypertension · China | 4 | Completed | 330 | |
| NCT00163202Coronary Artery Disease · Canada, Czechia, France and more | 4 | Completed | 330 | |
| NCT00163150Stroke · France | 4 | Completed | 128 | |
| NCT00159718Angina Pectoris · Croatia, Czechia, Estonia and more | 4 | Completed | 360 | |
| NCT00151502Alzheimer Disease · United States, Australia, Austria and more | 3 | Completed | 600 | |
| NCT00150384Hypertension · United States | 4 | Completed | 500 | |
| NCT00150371Hypercholesterolemia · Canada | 3 | Completed | 1,100 | |
| NCT00141232Diabetes Mellitus, Type 2 · United Kingdom | 4 | Completed | 810 | |
| NCT00141141Hypercholesterolemia · Italy | 4 | Completed | 383 | |
| NCT00136942Hyperlipidemias · Switzerland | 3 | Completed | 370 |
How it is read
Names in the registry
- “Atorvastatin”, 95 entries
- “atorvastatin”, 36 entries
- “Atorvastatin 20 mg”, 3 entries
- “Comparator: atorvastatin”, 3 entries
- “Atorvastatin 10 mg”, 3 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 48 studies
- Dyslipidemias, 15 studies
- Hyperlipidemias, 11 studies
- Diabetes Mellitus, Type 2, 9 studies
- Cardiovascular Diseases, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.